===
Issuer: CureVac / Key word(s): Study
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration
with GSK
2024-05-28 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration
with GSK

. Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine
candidate against influenza B strain
. Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study
in seasonal influenza
. Composition of vaccine candidate changed to match all three WHO-recommended flu strains, following
recommendation to exclude B/Yamagata lineage

TÜBINGEN, Germany/BOSTON, USA - May 28, 2024 - CureVac N.V. (Nasdaq: CVAC) ("CureVac"), a global biopharmaceutical
company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today
announced dosing of the first participant in a Phase 2 study of the multivalent seasonal influenza vaccine candidate
developed in collaboration with GSK. The study will assess targeted optimizations for improved immune responses of the
vaccine candidate against the relevant influenza B strain.
This new Phase 2 study in the joint CureVac/GSK seasonal influenza program has been initiated following interim data
from the Phase 2 part of the ongoing combined Phase 1/2 study in seasonal influenza reported on April 4, 2024. The
reported data showed that among younger and older adults, serum hemagglutinin inhibition (HAI) geometric mean titers
elicited by the vaccine candidate against influenza A strains numerically exceeded those of the applied licensed
comparator vaccines consistently across all tested dose levels. For influenza B strains, serum HAI geometric mean
titers were lower than those elicited by the licensed comparator vaccines across tested age groups and dose levels.
For the now initiated Phase 2 study, the design of the multivalent vaccine candidate has been changed to address all
three World Health Organization (WHO)-recommended influenza strains, following its recommendation from February 2024 to
exclude the influenza B/Yamagata lineage and apply a trivalent vaccine format going forward. The three remaining
influenza strains include two influenza A strains and one influenza B strain.
"The previously reported positive interim data of the Phase 2 part of the combined Phase 1/2 study in seasonal
influenza confirmed that our technology platform elicits strong overall antibody titers at well-tolerated dose levels,
underscoring the potential of our second-generation mRNA backbone in our collaborative seasonal influenza vaccine
program," said Dr. Myriam Mendila, Chief Scientific Officer of CureVac. "Historically, it's been challenging to target
influenza B strains with a potent vaccine strategy. We are making progress in adapting and optimizing our clinical
approach to address this challenge and improve performance against the remaining B strain."
The Phase 2 study assesses the reactogenicity, safety, and immunogenicity of different dose levels of a modified,
multivalent vaccine candidate, encoding antigens matched to all three WHO-recommended flu strains. The study will
include 250 healthy younger adults aged 18 to 64 and 250 healthy older adults aged 65 to 85. In each age group,
different dose levels will be tested in comparison to an age-appropriate, licensed comparator vaccine.
About CureVac
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more
than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical
purposes. The principle of CureVac's proprietary technology is the use of optimized mRNA as a data carrier to instruct
the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered
in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on
CureVac's second-generation mRNA technology. This collaboration was later extended to the development of
second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary
technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies,
antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has
more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland, and the U.S. Further
information can be found at www.curevac.com.
CureVac Media Contact
Patrick Perez, Junior Manager Public Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1831
patrick.perez@curevac.com
CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
Forward-Looking Statements CureVac
This press release contains statements that constitute "forward looking statements" as that term is defined in the
United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions,
expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned
subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH,
CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or
future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential
efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway,
growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology
such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would,"
"could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking
statements are based on management's current beliefs and assumptions and on information currently available to the
company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not
place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other
variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the
worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and
clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and
collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in
current and proposed legislation, regulations and governmental policies, pressures from increasing competition and
consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of
operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability
to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in
litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the
statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these
risks are outside of the company's control and could cause its actual results to differ materially from those it
thought would occur. The forward-looking statements included in this press release are made only as of the date hereof.
The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect future events or developments, except as
required by law.
For further information, please reference the company's reports and documents filed with the U.S. Securities and
Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      CureVac 

Friedrich-Miescher-Str. 15
72076 Tübingen
Germany
EQS News ID: 1912779

End of News EQS News Service

===
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1912779&application_name=news

END) Dow Jones Newswires

May 28, 2024 07:00 ET (11:00 GMT)